New data from Eli Lilly reveal that 63.5% of ulcerative colitis patients treated with Omvoh maintained disease clearance after four years of continuous treatment. Disease clearance means simultaneous symptom relief, and endoscopic and histologic remission, a high clinical standard linked to fewer hospitalizations and surgeries. This is the first IL-23p19 inhibitor to demonstrate such long-term durable remission, potentially changing the disease's long-term course. Eli Lilly is also exploring combination therapies and pediatric trials to further improve outcomes.
The US announced a phased tariff plan on imported generic drugs starting August 1, 2026, with zero tariffs for two years, followed by a 100% tariff in August 2028 and 200% in 2029. This move aims to encourage generic drugmakers to relocate production...
A new report reveals more than 180 companies are actively developing over 200 PD-1 and PD-L1 inhibitors, a class of immunotherapies that boost the immune system to fight cancer. These drugs target various cancers including lung, bladder, liver, and e...
Novo Nordisk has filed a federal lawsuit against Eli Lilly, accusing the company of misleading advertising for its GLP-1 drugs Zepbound and Mounjaro. Novo claims Lilly's ads use outdated data and unfairly compare Lilly's highest drug doses to lower d...
Novo Nordisk has filed a lawsuit against Eli Lilly, accusing the company of running misleading ads that inaccurately claim superior efficacy of Lilly's obesity and diabetes drugs compared to Novo's. The lawsuit targets ads that use outdated clinical ...
Atlas Healthcare Fund, managed by VST Capital, invested in Eli Lilly at around $350 per share in 2020, well before its GLP-1 drug tirzepatide became a major success. The stock now trades above $1,200, reflecting a gain of over 246%. This early invest...
